GCS-α-1 Antibody (D-9): sc-376502

GCS-α-1 Antibody (D-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects GCS-alpha-1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GCS-α-1 (D-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. GCS-alpha-1, a crucial component of guanylate cyclases, plays a significant role in cyclic guanosine monophosphate (cGMP) synthesis, vital for numerous physiological processes, including smooth muscle relaxation, neurotransmission, and platelet function. Located primarily in cytoplasm and membrane of cells, GCS-alpha-1 acts as a receptor for nitric oxide (NO), a key signaling molecule in cardiovascular system. GCS-alpha-1 and NO interaction is essential for regulating vascular tone and blood flow, making GCS-alpha-1 a critical target for therapeutic interventions in cardiovascular diseases. GCS-alpha-1 exists as a heme-containing heterodimer, composed of an α subunit (GCS-α-1) and a β subunit, with heme moiety facilitating NO activation. GCS-alpha-1 can be stimulated by carbon monoxide, which binds to heme group, albeit with weaker efficacy. Presence of allosteric activators, such as YC-1, further enhances enzymatic activity, underscoring regulation complexity and importance of understanding GCS-alpha-1 function in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GCS-α-1 Antibody (D-9) References:

1. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.  |  Abe, A., et al. 2000. Kidney Int. 57: 446-54. PMID: 10652021
2. Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses.  |  Bellamy, TC., et al. 2000. Proc Natl Acad Sci U S A. 97: 2928-33. PMID: 10717006
3. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation.  |  Lee, YC., et al. 2000. Proc Natl Acad Sci U S A. 97: 10763-8. PMID: 10995472
4. Subunits of the nitric oxide receptor, soluble guanylyl cyclase, expressed in rat brain.  |  Gibb, BJ. and Garthwaite, J. 2001. Eur J Neurosci. 13: 539-44. PMID: 11168561
5. Nitric oxide activates the beta 2 subunit of soluble guanylyl cyclase in the absence of a second subunit.  |  Koglin, M., et al. 2001. J Biol Chem. 276: 30737-43. PMID: 11406623
6. Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain.  |  Ibarra, C., et al. 2001. Brain Res. 907: 54-60. PMID: 11430885
7. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.  |  Martin, E., et al. 2001. Proc Natl Acad Sci U S A. 98: 12938-42. PMID: 11687640
8. A new form of guanylyl cyclase is preferentially expressed in rat kidney.  |  Yuen, PS., et al. 1990. Biochemistry. 29: 10872-8. PMID: 1980215
9. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells.  |  Schömel, N., et al. 2020. Sci Rep. 10: 8182. PMID: 32424263
10. UGCG modulates heart hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and the ERK signaling pathway.  |  Cui, S., et al. 2023. Cell Mol Biol Lett. 28: 71. PMID: 37658291
11. UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation.  |  Long, L., et al. 2025. Transl Oncol. 52: 102241. PMID: 39674092
12. Functional domains of soluble guanylyl cyclase.  |  Wedel, B., et al. 1995. J Biol Chem. 270: 24871-5. PMID: 7559610

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GCS-α-1 Antibody (D-9) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-GCS-α-1 Antibody (D-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GCS-α-1 Antibody (D-9) Specifications

Alternate Product Name: GCS-α-1

Product Clone Name: D-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-155

Epitope Target: GCS-α-1

Epitope Species: human

Product Reactivity/Detection: GCS-α-1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for GCS-α-1 Antibody (D-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin